Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies
Open Access
- 16 April 2021
- journal article
- review article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 14 (1) , 1-24
Abstract
Bispecific T cell engagers (BiTEs) are an innovative class of immunotherapeutics that redirect T cells to tumor surface antigens. While efficacious against certain hematological malignancies, limited bioavailability and severe toxicities have so far hampered broader clinical application, especially against solid tumors. Another emerging cancer immunotherapy are oncolytic viruses (OVs) which selectively infect and replicate in malignant cells, thereby mediating tumor vaccination effects. These oncotropic viruses can serve as vectors for tumor-targeted immunomodulation and synergize with other immunotherapies. In this article, we discuss the use of OVs to overcome challenges in BiTE therapy. We review the current state of the field, covering published preclinical studies as well as ongoing clinical investigations. We systematically introduce OV-BiTE vector design and characteristics as well as evidence for immune-stimulating and anti-tumor effects. Moreover, we address additional combination regimens, including CAR T cells and immune checkpoint inhibitors, and further strategies to modulate the tumor microenvironment using OV-BiTEs. The inherent complexity of these novel therapeutics highlights the importance of translational research including correlative studies in early-phase clinical trials. More broadly, OV-BiTEs can serve as a blueprint for diverse OV-based cancer immunotherapies.Keywords
Funding Information
- German National Science Foundation (EN-9111/2-2)
- Wilhelm Sander Foundation (2018.058.01)
This publication has 156 references indexed in Scilit:
- Nanobodies: Natural Single-Domain AntibodiesAnnual Review of Biochemistry, 2013
- CD19: a biomarker for B cell development, lymphoma diagnosis and therapyExperimental Hematology & Oncology, 2012
- Complex Spatial Dynamics of Oncolytic Viruses In Vitro: Mathematical and Experimental ApproachesPLOS Computational Biology, 2012
- Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocolBMC Cancer, 2012
- Systemic Delivery of Oncolytic Viruses: Hopes and HurdlesAdvances in Virology, 2012
- Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4Gene Therapy, 2011
- Targeting Tumor Vasculature With an Oncolytic VirusMolecular Therapy, 2011
- Current Good Manufacturing Practice Production of an Oncolytic Recombinant Vesicular Stomatitis Viral Vector for Cancer TreatmentHuman Gene Therapy, 2011
- Frequency of Adverse Events after Vaccination with Different Vaccinia StrainsPLOS Medicine, 2006
- ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour propertiesGene Therapy, 2003